Paradigm Clinical Research Announces Expansion of Site Locations
Paradigm Clinical Research announces the opening of its clinical research site in Littleton, CO, the company’s fourth location. The new site location complements the company’s long-standing site in Wheat Ridge, CO.
This expansion is a continuation of Paradigm Clinical Research’s growth strategy, which focuses on creating purpose-built research sites to fulfill the industry’s demand for study participants and the need for diverse populations and investigators. As part of this strategy, the company has partnered with Andy Fine, MD, who will serve as a principal investigator (PI) in Littleton. Fine is a primary care physician at Colorado Primary Health Care, which is the leading primary care group in the area, serving a large and diverse patient base.
Reference
Paradigm Clinical Research Announces Expansion of Site Locations. (2023, April 18). Paradigm Research.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
